Affordable Access

deepdyve-link
Publisher Website

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab.

Authors
  • Santegoets, Saskia Jam1
  • Stam, Anita Gm2
  • Lougheed, Sinéad M1
  • Gall, Helen1
  • Jooss, Karin3
  • Sacks, Natalie3
  • Hege, Kristen3
  • Lowy, Israel4
  • Scheper, Rik J5
  • Gerritsen, Winald R1
  • van den Eertwegh, Alfons Jm1
  • de Gruijl, Tanja D1
  • 1 Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • 2 Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands ; Department of Pathology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • 3 Cell Genesys Inc, South San Francisco, CA USA.
  • 4 Medarex, Bloomsbury, NJ/Bristol-Myers Squibb Company, Wallingford, CT USA.
  • 5 Department of Pathology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Type
Published Article
Journal
Journal for ImmunoTherapy of Cancer
Publisher
Springer (Biomed Central Ltd.)
Publication Date
2014
Volume
2
Pages
31–31
Identifiers
DOI: 10.1186/s40425-014-0031-3
PMID: 26196012
Source
Medline
Keywords
License
Unknown

Abstract

Our data demonstrate that DC and MDSC subsets are affected by prostate GVAX/ipilimumab therapy and that myeloid profiling may contribute to the identification of patients with possible clinical benefit of Prostate GVAX/ipilimumab treatment.

Report this publication

Statistics

Seen <100 times